Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL".

Massimiliano Bonifacio(University of Verona), G. Pizzolo, Lara Furlani(University of Verona), Alberto Zamò(University of Verona), Gabriele Corradi, Giuseppe Carli(Presidio Ospedaliero), Marco Chilosi(University of Verona), Achille Ambrosetti(International Extranodal Lymphoma Study Group), Francesca Moretta(University of Verona), Giuseppe Todeschini(University of Pisa), Federico Mosna(Paracelsus Medical University)
Unknown
January 1, 2011
Cited by 0

Related Papers

Aberrant Wnt/β-Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis
|American Journal Of Pathology|2003|708
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
|Blood|2003|490
Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure
|Respiration|2018|348
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194